Stopping Cancer Early – The Best Possible Investment


Posts Tagged ‘SPORES’

Early Cancer Detection Update for National Cancer Institute and National Institute of Health

November 29, 2012

The National Cancer Institute, under the National Institute of Health, plays a crucial role in cancer research throughout the United States. As the nation’s “investment in cancer,” NCI has quite a bit of ground to cover.  NCI’s annual budget is approximately $5 billion. In 2010, 7% of NCI’s budget was allocated to the Division of Cancer Prevention. The Early Detection Research Group is one of ten groups in this division, and the Early Detection Research Network (EDRN) is one of the division’s six major projects. This means that early detection research is receiving a fraction of that 7% budget.

Although early detection may not be their top focus, NCI has moved to make a more substantial investment in early detection research and technology, and is making headway in this area.  Additionally, NCI has collaborated with Canary Foundation on early detection projects.

NCI started EDRN to bring together multiple institutions working on early detection research. Early detection has many facets and therefore requires the work of leaders from many fields. By working together, different institutions can more effectively facilitate advances in early detection science and translate these advances into clinical practice. Canary Foundation operates in this same way, organizing multi-institutional studies and moving studies towards clinical practice.

The NCI has also developed accelerated programs called SPORES, or Specialized Programs of Research Excellence. SPORE studies are set up to be short-term (five years or less) and high-impact where they can translate quickly to clinical use and improve the lives of humans. Their objective is to reduce cancer incidence and mortality, while seeking to better the quality of life for cancer patients. Several of Canary Foundation’s programs and researchers are involved in important SPORE work including our Ovarian and Prostate Cancer Programs. More »